Evidence map›Paper›PMID 31571099›Full record

ArticlePituitary2019

MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.

George Kontogeorgos, Eleni Thodou, Mary Koutourousiou, Gregory Kaltsas, Andreas Seretis

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

George KontogeorgosFirst Propaepeudic Department of Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens, 75 Mikras Asias Str., 11527, Athens, Attica, Greece. gkonto@med.uoa.gr.
Eleni ThodouDepartment of Pathology, School of Medicine, University of Thessaly, Viopolis, 41110, Larissa, Thessaly, Greece.
Mary KoutourousiouDepartment of Neurological Surgery, University of Louisville, 220 Abraham Flexner Way, Louisville, KY, 40202, USA.
Gregory KaltsasFirst Propaepeudic Department of Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens, 75 Mikras Asias Str., 11527, Athens, Attica, Greece.
Andreas SeretisNeurosurgery Department, Henry Dunant Hospital, 107 Messogion Ave., 11527, Athens, Attica, Greece.
National and Kapodistrian University of Athens · GRHenry Dunant Hospital · GRNeurological Surgery · USUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTemozolomide (TMZ) is currently considered as a rational therapeutic option for patients with progressively aggressive pituitary adenomas and carcinomas not responding to conventional therapies. Administration of TMZ results in clinical response and improvement in survival of many of these patients depending upon the expression of the DNA repair enzyme O-6 methylguanine DNA transferase (MGMT). Low or negative MGMT immunoreactivity predicts responsiveness to TMZ therapy. Therefore, MGMT serves as a criterion to select candidate patients anticipating response to treatment. MATERIALS AND

methodsThe MGMT expression was investigated in 25 pituitary adenomas with Ki-67 labeling index more that 3% and p53 expression, using various antigen retrieval protocols. After direct application of the antibody, only one adenoma yielded positive for MGMT. However, after pretreatment of tissue sections with antigen retrieval protocols, another 3 adenomas, initially negative turned to positive.

conclusionsThese findings could explain lack of response to TMZ treatment in patients with false negative MGMT immunohistochemistry. Evaluation of tumor samples for MGMT expression should carefully be carried-out using the optimum immunohistochemical protocol to obtain consistent and reliable results that help to identify patients that could respond to TMZ therapy.

Indexed as

Antineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesFemaleHumansImmunohistochemistryMalePituitary NeoplasmsTemozolomideTumor Suppressor ProteinsAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTemozolomideTumor Suppressor ProteinsAntigen retrieval protocolsImmunohistochemistry Ki-67MGMTp53Temozolomide

Identifiers

PMID31571099
OpenAlexW2979256210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.